Atara Biotherapeutics appoints Kanya Rajangam as CMO
Dr. Rajangam joins Atara from Cleave Biosciences where she served as Chief Medical Officer, overseeing clinical development programs in hematologic and solid tumor malignancies.
Previously, Dr. Rajangam was a Senior Medical Director at Onyx Pharmaceuticals, where she played a key role in the successful FDA and EMA submissions of the multiple myeloma product KYPROLIS (carfilzomib).
Prior to this, Dr. Rajangam was Associate Medical Director at Exelixis, where she designed early-stage oncology clinical studies, including for COMETRIQ (cabozantinib) and COTELLIC (cobimetinib).
Throughout her career, Dr. Rajangam has worked closely with pharmaceutical partners including Amgen, Sanofi, Bristol-Myers Squibb and Genentech to advance oncology programs in all phases of clinical development.
After earning her medical degree from St. John’s Medical College in Bangalore, India, she completed a surgical residency, including a master’s thesis in renal transplantation, at the Postgraduate Institute of Medical Education and Research (India).
Dr. Rajangam then earned her doctorate in biomedical tissue engineering from Northwestern University. ■